SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq:PROG) today announced it has completed the divesture of a collection of novel, discovery-stage biochemical and bioinformatics technologies, including single-molecule detection, which are designed to enable next-generation rapid, low-cost assessment of biomolecules via liquid biopsy.
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
Globe Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here